Comparative Pharmacology
Head-to-head clinical analysis: CHOLETEC versus VASCORAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CHOLETEC versus VASCORAY.
CHOLETEC vs VASCORAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Choletec is a technetium-99m labeled iminodiacetic acid derivative used for hepatobiliary scintigraphy. It is taken up by hepatocytes via organic anion transporting polypeptides and excreted into bile canaliculi via multidrug resistance-associated protein 2, allowing visualization of the biliary system.
VASCORAY is a fixed combination of iodixanol and calcium sodium edetate. Iodixanol is a nonionic, dimeric, isotonic iodinated contrast medium that increases radiographic contrast by attenuating X-rays. Calcium sodium edetate chelates calcium, potentially reducing contrast-induced nephropathy risk.
1 gram intravenously every 8 hours; maximum 3 g/day.
0.5-1.0 mL/kg intravenously as a single dose, not to exceed 5 mL/kg total.
None Documented
None Documented
Terminal elimination half-life is approximately 16–24 hours; clinically, once-daily dosing achieves steady-state after 5–7 days, allowing for pharmacological effects on bile acid composition.
Terminal elimination half-life of 8-12 hours in patients with normal renal function; prolonged in renal impairment.
Primarily biliary (approx. 50–70% as unchanged drug and metabolites) with fecal elimination; renal excretion is minimal (<5% unchanged).
Primarily renal (90% unchanged), with 10% biliary/fecal.
Category C
Category C
Radiographic Contrast Agent
Radiographic Contrast Agent